Clinical research, innovative practice and IRB review: Identifying and respecting boundaries

American Journal of Transplantation

Volumn 7, Issue 4, 2007, Pages 748-750

  Ryan, C M ^a   Swanson, D P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; TACROLIMUS;

CLINICAL PRACTICE; CLINICAL RESEARCH; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33947576549     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01738.x     Document Type: Short Survey

References (5)

1. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6: 2409-2417.
2. Kirk AD, Light JA. Of ends and means. Am J Transplant 2006; 6: 2228-2229.
3. Lewens T. Distinguishing treatment from research: A functional approach. J Med Ethics 2006; 32: 424-429.
4. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont Report. Washington, D.C., U.S. Government Printing Office, 1979.
5. US Department of Health and Human Services: Protections of Human Subjects: 45 CFR Part 46, 1991.